Beta

Mereo biopharma group plcMREO.US Overview

US StockHealthcare
(No presentation for MREO)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

MREO AI Insights

MREO Overall Performance

MREO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MREO Recent Performance

-0.71%

Mereo biopharma group plc

-1.10%

Avg of Sector

-0.49%

S&P500

MREO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check MREO's Trend

MREO Key Information

MREO Valuation Metrics

MREO Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Price of MREO

MREO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MREO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.26
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
92.58
PB Ratio
1.20
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
73.60%
Net Margin
-8375.60%
Revenue Growth (YoY)
38.47%
Profit Growth (YoY)
155.24%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.26
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
92.58
PB Ratio
1.20
Price-to-FCF
-
Gross Margin
73.60%
Net Margin
-8375.60%
Revenue Growth (YoY)
38.47%
Profit Growth (YoY)
155.24%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is MREO's latest earnings report released?

    The most recent financial report for Mereo biopharma group plc (MREO) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MREO's short-term business performance and financial health. For the latest updates on MREO's earnings releases, visit this page regularly.

  • How much cash does MREO have?

    At the end of the period, Mereo biopharma group plc (MREO) held Total Cash and Cash Equivalents of 40.99M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of MREO?

    Mereo biopharma group plc (MREO)'s Free Cash Flow (FCF) for the period is -7.68M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 18.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MREO?

    The latest valuation data shows Mereo biopharma group plc (MREO) has a Price-To-Earnings (PE) ratio of -1.38 and a Price/Earnings-To-Growth (PEG) ratio of -0.5. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.